Two new bills aimed at increasing access to biosimilars and saving billions of dollars in out-of-pocket costs have been introduced in Congress. Both have been referred to committees for further review.
In the past 2 weeks, a pair of biosimilar bills have been introduced to Congress: HR 6179, which would establish a “shared savings” model to encourage physicians to switch their patients to lower cost biosimilars, and S 3466, which would allow $0 co-pays for seniors prescribed biosimilars under Medicare Part B.
HR 6179, the Increasing Access to Biosimilars Act of 2020, would direct CMS to implement a shared savings model for biosimilar prescriptions.
Shared savings is a payment strategy that offers providers a percentage of any net savings realized to encourage them to reduce healthcare spending for a defined patient population. A recent poll, conducted by HarrisX in February, found that 73% of Americans are in favor of sharing savings, a 5% increase from October 2019. The same poll found that 78% of Americans are in favor of $0 co-pays.
The Biosimilars Forum, an advocate of the bill, said that “by sharing savings from lower-cost biosimilars with patients and doctors, patients will benefit from more options for less costly treatments.”
Bill cosponsors, Representatives Tony Cárdenas, D-California; Richard Hudson, R-North Carolina; Brian Fitzpatrick, R-Pennsylvania; and Angie Craig, D-Minnesota, expect the legislation to encourage physicians to prescribe lower-cost medicines, including biosimilars.
“Prescription drug costs have been skyrocketing in recent years, adversely affecting every American. One of the most afflicted groups has been seniors, a majority of whom are on a fixed income and need medication to get through the day,” Fitzpatrick said in a statement. “I’m proud of the work we have done in this bipartisan bill, and I look forward to continuing to fight for our seniors.”
S 3466 was introduced in the Senate by Senators Martha McSally, R-Arizona, and Doug Jones, D-Alabama, and would waive all out-of-pocket expenses for biosimilar products for beneficiaries of Medicare Part B programs. The waiver would apply for the first 5 years that a biosimilar is on the market. This Senate legislation has a companion bill that was introduced in the House in October 2019.
“Congress continues to recognize that the savings potential of biosimilars is the right thing to do for patients, taxpayers, and the healthcare system at-large,” the Biosimilars Forum said in a statement.
A recent analysis showed that reducing patients’ out-of-pocket costs for biosimilars under Medicare Part B with this legislation could save up to $5.2 billion in taxpayer dollars over the next 10 years. The bill is also projected to save seniors as much as $3.3 billion in out-of-pocket costs over the same period, according to the Biosimilars Forum.
Since being introduced to Congress on March 10, HR 6179 has been referred to the Committee on Energy and Commerce as well as the Committee on Ways and Means for a period to be determined by House Speaker Nancy Pelosi. S 3466 has been referred to the Committee on Finance for further review.
The HarrisX poll results suggest that most Americans (65%) still do not know what biosimilars are.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.